

Pherecydes Pharma announces the first international approval of a compassionate treatment with its phages

The Swedish Medical Products Agency (SMPA) has given its approval to treat a compassionate case of osteoarticular infection of a prosthetic joint with the Company's anti-S. aureus phages

Nantes (France), April 28, 2022 – 6.00 pm CEST – Pherecydes Pharma (FR0011651694 - ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the first international approval of a compassionate treatment with its phages, in Sweden.

The Swedish Medical Products Agency (SMPA) has given its approval to treat a case of osteoarticular infection of a prosthetic joint with Pherecydes Pharma's anti-*S. aureus* phages. The treatment should be administered to the patient at Uppsala hospital in the coming days.

With the compassionate treatments continuing to be provided in France, Pherecydes Pharma is thus taking the number of patients treated to date to beyond 50.

Guy-Charles Fanneau de La Horie, Chairman of the Executive Board of Pherecydes Pharma, stated: "This first international approval for compassionate use with our phages is a major step for Pherecydes Pharma's development. Firstly, it is further proof of the growing global awareness of the health emergency caused by resistant bacterial infections. Indeed, countries' health organizations are closely monitoring this global health issue and are particularly receptive to innovations that provide a therapeutic response. This approval from the SMPA is also recognition of our phages' pharmaceutical quality, one of the criteria scrupulously followed by all health agencies. This decision also confirms that Pherecydes Pharma enjoys a growing international reputation and underscores our strategic approach focusing on compassionate treatment as the first step in positioning our phages prior to their European marketing authorization".


About Pherecydes Pharma

Founded in 2006, Pherecydes Pharma is a biotechnology company that develops treatments against resistant bacterial infections, responsible for many serious infections. The Company has developed an innovative approach, precision phage therapy, based on the use of phages, natural bacteria-killing viruses. Pherecydes Pharma is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two thirds of hospital-acquired resistant infections: *Staphylococcus aureus, Escherichia coli* and *Pseudomonas aeruginosa*. The concept of precision phage therapy has been successfully applied in several dozen patients in the context of compassionate use, under the supervision of the French National Agency for the Safety of Medicines (ANSM). Headquartered in Nantes, Pherecydes Pharma has a team of around twenty experts from the pharmaceutical industry, biotechnology sector and academic research.

For more information, www.pherecydes-pharma.com









W

Contacts

Pherecydes Pharma

Guy-Charles Fanneau de La Horie Chairman of the Executive Board investors@pherecydes-pharma.com

NewCap

Dusan Oresansky / Olivier Bricaud Investor Relations pherecydes@newcap.eu

T.: +33 1 44 71 94 92

NewCap

Arthur Rouillé Media Relations

<u>pherecydes@newcap.eu</u>
T.: +33 1 44 71 00 15

Disclaimer

This press release contains non-factual elements, including, but not limited to, certain statements regarding future results and other future events. These statements are based on the current vision and assumptions of the management of the Company. They incorporate known and unknown risks and uncertainties that could result in significant differences in results, profitability and expected events. In addition, Pherecydes Pharma, its shareholders and its affiliates, directors, officers, counsels and employees have not verified the accuracy of, and make no representations or warranties about, statistical information or forecast information contained within this news release and that originates or is derived from third party sources or industry publications; these statistical data and forecast information are only used in this press release for information purposes. Finally, this press release may be drafted in French and in English. In the event of differences between the two texts, the French version will prevail.



